webinar
Oct. 27-28, 2025, Boston, MA, USA - Booth 114.
Read More
  1. Home
  2. Products
  3. ADC Cytotoxin with Linker
  4. Cys-MC-MMAF

Cys-MC-MMAF

  CAS No.: 1160590-05-5   Cat No.: BADC-01432   Purity: ≥95% 4.5  

Cys-MC-MMAF is the released payload of AlMcMMAF, an anti-5T4 humanized A1 antibody that is conjugated to microtubule MMAF destruction via a maleimidocaproyl linker. It has antitumor effects on two tumor mouse models (H1975 and MDA-MB-361-DYT2).

Cys-MC-MMAF

Structure of 1160590-05-5

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
ADC Cytotoxin with Linker
Molecular Formula
C52H83N7O13S
Molecular Weight
1046.32
Shipping
Store at -20°C, protect from light

* For research and manufacturing use only. We do not sell to patients.

Size Price Stock Quantity
-- $-- In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

Popular Publications Citing BOC Sciences Products
Synonyms
L-Phenylalanine, N-[6-[3-[[(2R)-2-amino-2-carboxyethyl]thio]-2,5-dioxo-1-pyrrolidinyl]-1-oxohexyl]-N-methyl-L-valyl-L-valyl-(3R,4S,5S)-3-methoxy-5-methyl-4-(methylamino)heptanoyl-(αR,βR,2S)-β-methoxy-α-methyl-2-pyrrolidinepropanoyl-; N-[6-[3-[[(2R)-2-Amino-2-carboxyethyl]thio]-2,5-dioxo-1-pyrrolidinyl]-1-oxohexyl]-N-methyl-L-valyl-L-valyl-(3R,4S,5S)-3-methoxy-5-methyl-4-(methylamino)heptanoyl-(αR,βR,2S)-β-methoxy-α-methyl-2-pyrrolidinepropanoyl-L-phenylalanine; S-(1-(6-(((S)-1-(((S)-1-(((3R,4S,5S)-1-((S)-2-((1R,2R)-3-(((S)-1-carboxy-2-phenylethyl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxoheptan-4-yl)(methyl)amino)-3-methyl-1-oxobutan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)(methyl)amino)-6-oxohexyl)-2,5-dioxopyrrolidin-3-yl)-L-cysteine; Denintuzumab mafodotin; Vorsetzumab Mafodotin; Vorsetuzumab mafodotin; Cys-McMMAF
IUPAC Name
(2S)-2-[[(2R,3R)-3-[(2S)-1-[(3R,4S,5S)-4-[[(2S)-2-[[(2S)-2-[6-[3-[(2R)-2-amino-2-carboxyethyl]sulfanyl-2,5-dioxopyrrolidin-1-yl]hexanoyl-methylamino]-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methoxy-5-methylheptanoyl]pyrrolidin-2-yl]-3-methoxy-2-methylpropanoyl]amino]-3-phenylpropanoic acid
Canonical SMILES
CCC(C)C(C(CC(=O)N1CCCC1C(C(C)C(=O)NC(CC2=CC=CC=C2)C(=O)O)OC)OC)N(C)C(=O)C(C(C)C)NC(=O)C(C(C)C)N(C)C(=O)CCCCCN3C(=O)CC(C3=O)SCC(C(=O)O)N
InChI
InChI=1S/C52H83N7O13S/c1-12-32(6)45(38(71-10)27-41(61)58-25-19-22-37(58)46(72-11)33(7)47(63)54-36(52(69)70)26-34-20-15-13-16-21-34)57(9)50(66)43(30(2)3)55-48(64)44(31(4)5)56(8)40(60)23-17-14-18-24-59-42(62)28-39(49(59)65)73-29-35(53)51(67)68/h13,15-16,20-21,30-33,35-39,43-46H,12,14,17-19,22-29,53H2,1-11H3,(H,54,63)(H,55,64)(H,67,68)(H,69,70)/t32-,33+,35-,36-,37-,38+,39?,43-,44-,45-,46+/m0/s1
InChIKey
BXTJCSYMGFJEID-XMTADJHZSA-N
Density
1.25±0.1 g/cm3
Solubility
Soluble in DMSO, Water
Appearance
Solid
Storage
Store at -20°C, protect from light
Boiling Point
1172.4±65.0°C at 760 mmHg

Cys-MC-MMAF, a potent cytotoxic agent utilized in targeted cancer therapies, shines in the realm of antibody-drug conjugates (ADCs). Here are four key applications of Cys-MC-MMAF:

Cancer Treatment: Embedded within antibody-drug conjugates, Cys-MC-MMAF forms a lethal bond with an antibody that meticulously targets cancerous cells. Upon fusion with the targeted cell, the ADC undergoes internalization, freeing Cys-MC-MMAF to unleash its cytotoxic prowess within. This targeted strategy not only minimizes harm to healthy cells but also amplifies the effectiveness of cancer therapy by optimizing the destruction of malignant cells.

Research and Development of ADCs: A cornerstone in the realm of antibody-drug conjugate innovation, Cys-MC-MMAF serves as an indispensable tool for crafting and evaluating novel ADCs. Researchers harness its potency to probe diverse antibody conjugates, fine-tuning their therapeutic efficacy. Acting as a prototype compound, Cys-MC-MMAF facilitates the meticulous assessment of ADCs’ strength and selectivity in preliminary research studies, setting the stage for enhanced cancer treatment modalities.

In Vivo Tumor Models: Employed within animal models, Cys-MC-MMAF plays a pivotal role in deciphering the pharmacokinetic and pharmacodynamic dynamics of emerging ADCs. Through in-depth in vivo evaluations, researchers unravel the distribution, efficacy, and toxicology profiles of these conjugates, a critical step in transitioning ADCs from experimental stages to clinical trials. This investigative process lays the groundwork for advancing the efficacy and safety of future cancer treatments.

Mechanistic Studies: Delving into the intricate workings of ADCs, researchers rely on Cys-MC-MMAF to unravel the mechanisms underlying their actions and potential resistance factors. By scrutinizing how cancer cells interact with and process the drug, as well as anticipating the emergence of treatment resistance, scientists pave the way for designing sophisticated next-generation ADCs with heightened effectiveness in combating cancer.

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Calculate
The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Calculate

Related Products

Contact our experts today for pricing and comprehensive details on our ADC offerings.

You May Also Be Interested In

From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.

ADC Payload Development Biological Payload ADC Linker–Payload Conjugation ADC Linker Development Chemical Payload Enzyme Cleavable Linker Cathepsin B Cleavable Linker/Peptide Linker Phosphatase Cleavable Linker β-Glucuronide Linker β-Galactosidase Cleavable Linker

Unlock Deeper ADC Insights

Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.

Maytansine and Its Analogues Linkers - A Crucial Factor in Antibody–Drug Conjugates Cytotoxic Agents Used in Antibody–Drug Conjugates Exatecan Mesylate in ADCs: A New Topo I Inhibitor What is Calicheamicin? What is Monomethyl Auristatin E (MMAE)? What is Monomethyl Auristatin F (MMAF)? What is Pyrrolobenzodiazepine (PBD)? Antiviral Potential of Thapsigargin in COVID-19 Research In-Depth Review of ADC Linkers: Types, Mechanisms, and Research Progress

Explore More ADC Products

Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.

ADC Cytotoxin

ADC Cytotoxin

Powerful Targeted Cancer Solutions

ADC Cytotoxin with Linker

ADC Cytotoxin with Linker

Enhanced Stability And Efficacy

ADC Linker

ADC Linker

Precise Conjugation For Success

Antibody-Drug Conjugates (ADCs)

Antibody-Drug Conjugates (ADCs)

Maximized Therapeutic Performance

Auristatins

Auristatins

Next-Level Tubulin Inhibition

Calicheamicins

Calicheamicins

High-Impact DNA Targeting

Camptothecins

Camptothecins

Advanced Topoisomerase Inhibition

Daunorubicins / Doxorubicins

Daunorubicins / Doxorubicins

Trusted Anthracycline Payloads

Duocarmycins

Duocarmycins

Potent DNA Alkylation Agents

Maytansinoids

Maytansinoids

Superior Microtubule Disruption

Pyrrolobenzodiazepines

Pyrrolobenzodiazepines

Ultra-Potent DNA Crosslinkers

Traditional Cytotoxic Agents

Traditional Cytotoxic Agents

Proven Chemotherapy Solutions

Cleavable Linker

Cleavable Linker

Precise Intracellular Drug Release

Non-Cleavable Linker

Non-Cleavable Linker

Exceptional Long-Term Stability

Historical Records: Mal-PEG2-Val-Cit-PABA-PNP | N-Succinimidyl 3-maleimidopropionate | Lorvotuzumab mertansine | Polatuzumab vedotin | PC SPDP-NHS carbonate ester | Disitamab vedotin | Fmoc-Val-Ala-PAB-PNP | 1-(4-((3-(dimethylcarbamoyl)pyridin-4-yl)disulfanyl)pentanoyloxy)-2,5-dioxopyrrolidine-3-sulfonic acid | MC-Alkyl-Hydrazine Modified MMAF | Cys-MC-MMAF
Send Inquiry
Verification code
Inquiry Basket
loading Loading ......
Delete selectedGo to checkout